Early CAR T-cell toxicity
| Early CAR T-cell toxicity . | CAR T-cell patients N = 280 . |
|---|---|
| CRS diagnosis, n (%) | 239 (85) |
| CRS grade, n (%) | |
| 1 | 102 (43) |
| 2 | 125 (52) |
| 3 | 8 (3) |
| 4 | 4 (2) |
| Days to maximum grade CRS, median (range) | 5 (0-12) |
| Tocilizumab for CRS, n (%) | 180 (75) |
| Tocilizumab doses, median (range) | 2 (1-4) |
| Corticosteroids for CRS, n (%) | 118 (49) |
| ICANS diagnosis, n (%) | 153 (55) |
| Days to onset, median (range) | 6 (0-34) |
| ICANS grade, n (%) | |
| 1 | 33 (22) |
| 2 | 34 (22) |
| 3 | 86 (56) |
| Corticosteroids for ICANS, n (%) | 103 (67) |
| Early CAR T-cell toxicity . | CAR T-cell patients N = 280 . |
|---|---|
| CRS diagnosis, n (%) | 239 (85) |
| CRS grade, n (%) | |
| 1 | 102 (43) |
| 2 | 125 (52) |
| 3 | 8 (3) |
| 4 | 4 (2) |
| Days to maximum grade CRS, median (range) | 5 (0-12) |
| Tocilizumab for CRS, n (%) | 180 (75) |
| Tocilizumab doses, median (range) | 2 (1-4) |
| Corticosteroids for CRS, n (%) | 118 (49) |
| ICANS diagnosis, n (%) | 153 (55) |
| Days to onset, median (range) | 6 (0-34) |
| ICANS grade, n (%) | |
| 1 | 33 (22) |
| 2 | 34 (22) |
| 3 | 86 (56) |
| Corticosteroids for ICANS, n (%) | 103 (67) |